1. Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding
- Author
-
Yuu Shimozuma, Ikuya Sugiura, Jun Arai, Masashi Sakaki, Shojiro Uozumi, Hitoshi Yoshida, Hisako Nozawa, Ryosuke Muroyama, Yuki Ichikawa, Yoko Nakajima, Yumi Otoyama, Masayuki Tojo, Atsushi Kajiwara, Kaku Goto, Manabu Uchikoshi, Naoya Kato, and Ryo Nakagawa
- Subjects
Cancer Research ,Carcinoma, Hepatocellular ,Leukotriene D4 ,Combination therapy ,Hepatocellular carcinoma ,Pyridines ,medicine.medical_treatment ,Immunology ,Down-Regulation ,Targeted therapy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Downregulation and upregulation ,Cell Line, Tumor ,Regorafenib ,Disintegrin ,Humans ,Immunology and Allergy ,Medicine ,030304 developmental biology ,0303 health sciences ,Leukotriene C4 ,biology ,MHC class I-related chain A ,business.industry ,Phenylurea Compounds ,Histocompatibility Antigens Class I ,Liver Neoplasms ,Membrane Proteins ,Hep G2 Cells ,Sheddase ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Killer Cells, Natural ,ADAM Proteins ,A disintegrin and metalloprotease 9 ,Treatment Outcome ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Cancer research ,biology.protein ,Leukotriene Antagonists ,Original Article ,business ,Genome-Wide Association Study - Abstract
In our previous genome-wide association study, we demonstrated the association between MHC class I-related chain A (MICA) and hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C. Increasing membrane-bound MICA (mMICA) in cancer cells by reducing MICA sheddases facilitates natural killer (NK) cell-mediated cytotoxicity. Our recent study clarified that A disintegrin and metalloproteases (ADAM), including ADAM9, are MICA sheddases in HCC, and that the suppression of ADAMs increases mMICA, demonstrating the rationality of mMICA-NK targeted therapy. Furthermore, we showed that regorafenib suppresses ADAM9 transcriptionally and translationally. A library of FDA-approved drugs was screened for more efficient inhibitors of ADAM9. Flow cytometry evaluation of the expression of mMICA after treatment with various candidate drugs identified leukotriene receptor antagonists as potential ADAM9 inhibitors. Furthermore, leukotriene receptor antagonists alone or in combination with regorafenib upregulated mMICA, which was in turn downregulated by leukotriene C4 and D4 via ADAM9 function. Our study demonstrates that leukotriene receptor antagonists could be developed as novel drugs for immunological control and suppression of ADAM9 in HCC. Further, leukotriene receptor antagonists should be explored as combination therapy partners with conventional multi-kinase inhibitors for developing therapeutic strategies with enhanced efficacies for HCC management and treatment. Electronic supplementary material The online version of this article (10.1007/s00262-020-02660-2) contains supplementary material, which is available to authorized users.
- Published
- 2020
- Full Text
- View/download PDF